INDV Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Indivior Pharmaceuticals, Inc (INDV), detailing its revenue breakdown, profitability margins, and a comparison with competitors. SUBLOCADE is identified as the largest revenue contributor, and the company's gross margin stands at 73.57%. The article also benchmarks INDV's financial performance against industry leaders like ACAD and SYRE.
Hennion & Walsh Asset Management Inc. Purchases 96,177 Shares of Indivior PLC $INDV
Hennion & Walsh Asset Management Inc. significantly increased its stake in Indivior PLC by 43.4%, purchasing an additional 96,177 shares to hold a total of 317,600 shares valued at $11.395 million. This move is supported by accelerated insider buying activity in early January and broadly positive analyst ratings, with an average price target of $39.33. Indivior recently surpassed quarterly EPS and revenue estimates, further bolstering investor confidence.
SG Americas Securities LLC Buys 363,829 Shares of Indivior PLC $INDV
SG Americas Securities LLC significantly increased its stake in Indivior PLC by 752.2% in Q4, acquiring 363,829 shares to now hold 412,197 shares valued at approximately $14.79 million. Company insiders also showed confidence, purchasing 5,842 shares worth about $203,342 in the last three months, including directors Daniel Ninivaggi and David Wheadon. Indivior surpassed EPS and revenue estimates in its recent quarter, leading analysts to maintain an average "Buy" rating with a consensus target price of $39.33.
Suboxone Market Size Forecasts 2026-2033: Analyzing Industry Growth and Trends | Indivior PLC, Dr. Reddys Laboratories Ltd., Amneal Pharmaceuticals LLC., Mylan N.V.
This report from Coherent Market Insights forecasts the Suboxone Market size from 2026 to 2033, analyzing industry growth and trends. It provides key insights, market segmentation by type, application, and region, and profiles major companies like Indivior PLC and Dr. Reddys Laboratories Ltd. The study aims to help decision-makers navigate the evolving market and capitalize on future opportunities.
Indivior PLC Stock Faces Uncertainty Amid U.S. Domicile Shift and OUD Market Focus
Indivior PLC is moving its domicile to the U.S. to align its corporate structure with its primary revenue base and capitalize on specialty pharmaceuticals for opioid use disorder (OUD) treatments, specifically focusing on SUBLOCADE. This strategic shift, approved by shareholders and awaiting court sanction, aims to streamline operations, enhance investor appeal, and reduce cross-border complexities. The company's "Action Agenda" prioritizes SUBLOCADE growth and operational efficiency while expanding its pipeline to address broader mental health therapies.
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV)
This article analyzes the historical performance of investing $1,000 in Indivior Pharmaceuticals Inc. (INDV) over various periods, showing significant returns over 1, 5, and 10 years, outperforming the S&P 500. It also provides a detailed overview of Indivior PLC, highlighting its focus on opioid use disorder treatments, key products like SUBLOCADE, operational strategies under the Indivior Action Agenda, and its financial and regulatory profile.
Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq
Indivior, a pharmaceutical company, has announced its intention to delist from the London Stock Exchange. The company will maintain its primary listing on the Nasdaq, reflecting a strategic shift towards the U.S. market.
Goldentree Asset Management LP Makes New Investment in Indivior PLC $INDV
Goldentree Asset Management LP has acquired a new position in Indivior PLC, purchasing 1,771,482 shares valued at approximately $42.63 million, making it their 10th largest holding. Indivior (NASDAQ:INDV) shows strong institutional and insider support, with 60.33% of shares held by institutions and recent insider purchases. The company also reported better-than-expected Q3 earnings and revenue, contributing to a consensus "Moderate Buy" rating from analysts with an average price target of $39.33.
Indivior (NASDAQ:INDV) Upgraded by Zacks Research to "Strong-Buy" Rating
Zacks Research upgraded Indivior (NASDAQ:INDV) to a "strong-buy" rating, with other analysts like HC Wainwright and Northland also raising price targets. The company beat quarterly earnings and revenue estimates, though the stock opened slightly down. Insider buying and increased institutional holdings, particularly by Invesco, indicate growing confidence in Indivior.
Indivior PLC Stock (ISIN: US45580R1068) Sees Surge in Institutional Interest and Trading Volume
Indivior PLC (ISIN: US45580R1068) is experiencing increased institutional interest and trading volume, particularly on Xetra, driven by major stake boosts from funds like Melqart and Mangrove Partners. Despite mixed analyst targets, the company maintains a "Moderate Buy" consensus. The specialty pharmaceutical firm focuses on opioid use disorder treatment, with its business model, cash flow, and market dynamics suggesting potential undervaluation for investors.
INDV SEC Filings - Indivior Pharmaceuticals Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access SEC filings for Indivior Pharmaceuticals Inc. (INDV), including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details how the company, focused on opioid use disorder treatments, uses these filings to report financial results, strategic initiatives, and governance changes. The platform also offers AI-powered summaries to help users quickly understand key points from these regulatory disclosures.
Melqart Asset Management UK Ltd Increases Position in Indivior PLC $INDV
Melqart Asset Management UK Ltd significantly increased its stake in Indivior PLC (NASDAQ:INDV) by 268.2% in Q3, now holding 616,863 shares valued at approximately $14.87 million. Indivior recently surpassed Q3 earnings and revenue expectations, reporting $0.82 EPS against a $0.65 consensus and $358.0 million revenue against $305.62 million. Analyst sentiment for Indivior remains positive, with a "Moderate Buy" consensus rating and an average price target of $39.33, indicating potential for continued growth.
INDV SEC Filings - Indivior Pharmaceuticals Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Indivior Pharmaceuticals (INDV) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It offers direct access to regulatory disclosures, focusing on the company's financial results, strategic initiatives, and governance changes, especially concerning its opioid use disorder treatments. The platform also enhances these documents with AI-powered summaries to help users quickly understand key points.
Indivior To Pay $300M To Settle Suboxone Opioid Marketing Claims By DOJ, States
Indivior, the maker of the opioid addiction treatment Suboxone, has agreed to pay an additional $300 million to settle allegations from various states regarding false advertising. This settlement follows an earlier $600 million agreement with the federal government over similar charges of aggressive and deceptive marketing practices for Suboxone. The states accused Indivior of misleading regulators and the medical community about the drug's safety profile and risks, particularly concerning its abuse potential and claims about its film form being more abuse-resistant than the pill.
Indivior PLC Stock (ISIN: US45580R1068) Drops 6% as $450M Convertible Notes Offering Signals Capital
Indivior PLC's stock fell 6% after announcing an upsized $450 million convertible senior notes offering. The company plans to use the proceeds for debt repayment, share buybacks, and general corporate purposes, which has raised concerns among investors about potential equity dilution. Despite the stock drop, analysts remain split, with some maintaining bullish ratings due to resolved legacy issues and strong Q4 2025 results, primarily driven by SUBLOCADE sales.
INDIVIOR PLC disclosed today that the company plans to publicly offer convertible senior notes due 2031 with a total amount of $400 million.
INDIVIOR PLC announced its plan to publicly offer $400 million in convertible senior notes due 2031. This strategic move aims to enhance the company's capital structure and secure financing for future business expansion initiatives.
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB
The Opioid Use Disorder market is projected to grow significantly, from USD 3.83 billion in 2025 to USD 6.87 billion by 2032, at a CAGR of 8.7%. A new report from Coherent Market Insights provides a comprehensive analysis of the market, including growth drivers, restraints, trends, key players, and regional outlooks. The study aims to help businesses make informed decisions and identify investment opportunities in the expanding OUD market.
INDIVIOR PLC disclosed today that the company plans to publicly offer convertible senior notes due 2031 with a total amount of $400 million.
INDIVIOR PLC announced its plan to publicly offer $400 million in convertible senior notes due 2031. This move aims to optimize the company's capital structure and secure funding for future business expansion. The disclosure was made on March 12, 2026.
Indivior (NASDAQ:INDV) Director Stuart Kingsley Buys 940 Shares
Indivior (NASDAQ:INDV) Director Stuart Kingsley purchased 940 shares of the company's stock on March 6th at an average price of $31.86, increasing his stake by 20.25% to 5,582 shares. The company recently reported strong earnings, beating analyst expectations with $0.82 EPS and $358 million in revenue, and analysts predict continued growth with a consensus "Moderate Buy" rating and an average target price of $39.33. This insider transaction and positive financial performance highlight investor confidence and potential upside for Indivior.
Victory Capital Management Inc. Makes New $19.44 Million Investment in Indivior PLC $INDV
Victory Capital Management Inc. has initiated a new $19.44 million investment in Indivior PLC (NASDAQ:INDV), acquiring 806,191 shares. This comes amidst recent insider buying, analyst upgrades, and strong quarterly earnings that surpassed expectations. Analysts maintain a "Moderate Buy" rating with an average target price near $39.33, indicating a positive outlook for the specialty pharmaceutical company.
Claret Asset Management Corp Has $18.92 Million Stake in Indivior PLC $INDV
Claret Asset Management Corp significantly increased its stake in Indivior PLC (NASDAQ:INDV) by 5.4% in Q3, now holding 784,588 shares valued at $18.92 million, making it their 13th largest holding. Institutional investors collectively own 60.33% of the company, and insiders recently acquired shares, indicating strong confidence. Analysts maintain a "Moderate Buy" rating with a consensus target price of $39.33, following Indivior's recent beat on quarterly earnings and revenue estimates.
Vanguard Group Inc. Has $83.10 Million Holdings in Indivior PLC $INDV
Vanguard Group Inc. reduced its stake in Indivior PLC by 38.6% in the third quarter, now holding 3.47 million shares valued at $83.1 million, while institutional investors collectively own about 60.3% of the stock. Company insiders, including Directors Barbara Ryan and Keith Humphreys, recently purchased shares. Analysts are generally bullish on Indivior, with a consensus target price of $39.33, following the company's strong quarterly earnings beat.
Global Transdermal Skin Patch Market Size, Growth, Trends &
A new study report on the Transdermal Skin Patch Market Demand 2024-2032 provides a comprehensive overview of the market size, trends, competition, and forecast. The report details key segments, market share, topological analysis, and primary and secondary drivers, alongside insights into leading businesses, product types, and end-user market segmentation. It covers market growth scope, import/export dynamics, and includes a competitive analysis for the global Transdermal Skin Patch industry.
Indivior To Pay $300M To Settle Suboxone Opioid Marketing Claims By DOJ, States
Indivior has agreed to pay $300 million to settle allegations from several states that it falsely advertised its opioid addiction treatment, Suboxone, as safer and less prone to abuse. This state settlement follows a previous $600 million agreement with the federal government over aggressive and deceptive marketing practices. The states accused Indivior of improperly using Medicaid funds and misleading medical professionals about the drug's safety profile and risks, particularly concerning the Suboxone Sublingual Film and its tablet form.
Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Indivior PLC (NASDAQ:INDV) has received a consensus "Moderate Buy" recommendation from analysts, with six out of seven firms issuing a buy rating and one a hold rating. The average twelve-month price target for the stock is $39.3333. Despite a recent 3.5% stock drop, the company exceeded Q4 earnings expectations and saw significant insider buying activity in January.
Quantbot Technologies LP Makes New Investment in Indivior PLC $INDV
Quantbot Technologies LP has acquired a new stake in Indivior PLC, purchasing 127,237 shares valued at approximately $3.068 million. This investment makes Quantbot Technologies LP the owner of 0.09% of Indivior. Other institutional investors have also recently modified their holdings in Indivior, and Wall Street analysts have issued a consensus "Moderate Buy" rating with a target price of $39.33.
Equities Analysts Issue Forecasts for Indivior Q4 Earnings
Equities analysts have issued forecasts for Indivior's (NASDAQ:INDV) Q4 earnings, with Northland Securities slightly lowering its EPS estimate to $0.70. Indivior reported Q4 EPS of $0.82, beating consensus estimates of $0.65, and revenue of $358 million, exceeding estimates of $305.62 million. The company currently holds a "Moderate Buy" consensus rating with an average target price of $39.33, and recent insider purchases have been noted.
Indivior Earnings Call: Profits Surge as SUBLOCADE Leads
Indivior's latest earnings call revealed record revenues for the company and its leading product, SUBLOCADE, alongside significant profitability gains. While facing challenges from older products and restructuring costs, the company aims for disciplined expansion and strong cash generation in 2026, driven by SUBLOCADE's commercial momentum and tight cost control. However, investors will need to consider risks such as product runoff, gross-to-net volatility, and concentration risk due to heavy reliance on SUBLOCADE.
Indivior earnings ahead: Investors eye SUBLOCADE growth story By Investing.com
Indivior PLC is poised to release its Q4 and full-year 2025 earnings, with investors keenly focused on the company's ability to achieve ambitious margin expansion following a period of restructuring and legal settlements. Analysts anticipate earnings of $0.67 per share on revenue of $305.62 million, and a significant part of the growth strategy hinges on the continued success of SUBLOCADE, an opioid use disorder treatment, especially with recent FDA label changes. The report will assess if the company's shift from restructuring to an "execution and earnings story" can offset revenue headwinds from portfolio simplification.
Indivior PLC $INDV Shares Sold by Clark Estates Inc. NY
Clark Estates Inc. NY significantly reduced its holding in Indivior PLC, selling 50,000 shares which now account for 0.11% of Indivior's stock and 0.8% of Clark Estates' portfolio. This comes despite recent insider buying from directors and a "Moderate Buy" consensus analyst rating with a target price of $39.33. Indivior, a specialty pharmaceutical company focused on addiction treatments, is currently trading around $33.89.
Indivior PLC Just Spiked: What Wall Street Isn’t Telling You Yet
Indivior PLC is drawing significant attention in the pharmaceutical and investment sectors due to recent legal developments, share buybacks, and its focus on opioid treatment. The company, primarily operating in the US opioid use disorder market, faces high risks but also potential for turnaround if its long-acting treatment, Sublocade, continues strong growth and legal hurdles recede. US investors are advised to conduct thorough research given the stock's volatility and its dependence on American healthcare policies.
Indivior PLC Just Spiked: What Wall Street Isn’t Telling You Yet
Indivior PLC, a UK-based specialty pharma company focused on opioid use disorder treatments, has seen a recent spike due to legal developments, share buybacks, and plans for a primary US listing. The company's business is heavily concentrated in the American market with its flagship product, Sublocade. Investors are eyeing it as a high-risk, high-reward play in the ongoing US opioid crisis.
Suboxone: History, controversy, and open questions
This comprehensive review article delves into the history, controversies, and unanswered questions surrounding Suboxone, a medication crucial for treating opioid use disorder (OUD). It explores the pharmacological and legislative evolution of buprenorphine, the active ingredient in Suboxone, and critically examines its efficacy, side effect profile, and the persistent societal stigma associated with medication-assisted treatment (MAT). The authors highlight the ongoing opioid epidemic's severity and argue for long-term buprenorphine treatment based on current evidence-based medicine, while also acknowledging the complex psychological dimensions of addiction beyond purely pharmacological solutions.
Persistent Asset Partners Ltd Acquires Shares of 58,409 Indivior PLC $INDV
Persistent Asset Partners Ltd has acquired 58,409 shares of Indivior PLC (NASDAQ:INDV) valued at approximately $1.41 million, making it 1.0% of the fund's holdings. Institutional investors collectively own 60.33% of the company, with other major purchases by Federated Hermes Inc. and Pacer Advisors Inc. The stock currently trades around $34.44, and analysts have a consensus "Moderate Buy" rating with an average target price of $39.33.
New York State Common Retirement Fund Sells 56,140 Shares of Indivior PLC $INDV
The New York State Common Retirement Fund reduced its stake in Indivior PLC (NASDAQ:INDV) by 59.4%, selling 56,140 shares and now holding 38,400 shares valued at $926,000. This comes as several other institutional investors increased their positions in Indivior, which sees 60.33% institutional ownership. Analysts maintain a "Moderate Buy" rating with an average target price of $39.33, while company insiders have also recently purchased shares.
Jackson Creek Investment Advisors LLC Buys Shares of 60,890 Indivior PLC $INDV
Jackson Creek Investment Advisors LLC has acquired 60,890 shares of Indivior PLC (NASDAQ:INDV) for approximately $1.47 million in the third quarter. This move comes as Indivior maintains a "Moderate Buy" consensus rating from analysts, despite a recent downgrade from Zacks Research, with insiders also increasing their holdings. The specialty pharmaceutical company, focused on addiction treatments, is currently trading around $35 with a market capitalization of $4.38 billion.
Federated Hermes Inc. Makes New $8.12 Million Investment in Indivior PLC $INDV
Federated Hermes Inc. has made a new $8.12 million investment in Indivior PLC, acquiring 336,797 shares in Q3, representing 0.24% of the company. Indivior recently surpassed earnings and revenue estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $39.33. Insider buying by two directors further indicates sustained investor interest in the specialty pharmaceutical company.
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Pharmaceuticals, Inc. announced its intention to report fourth-quarter and full-year 2025 financial results on February 26, 2026, at 7:00 a.m. U.S. EST. Following the release, a live webcast presentation will be hosted at 8:00 a.m. U.S. EST by CEO Joe Ciaffoni and other leadership members. Details for accessing the webcast and presentation replay are available on the company's website.
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Pharmaceuticals, Inc. announced it will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release, CEO Joe Ciaffoni and other leadership team members will host a live webcast presentation at 8:00 a.m. U.S. EST, accessible via the company’s website. Registrants can also access the presentation telephonically.
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Pharmaceuticals Inc. will release its fourth quarter and full-year 2025 financial results on February 26, 2026, at 7:00 a.m. U.S. EST. Following the release, the leadership team will host a live webcast presentation at 8:00 a.m. U.S. EST, accessible via the company's website. Indivior specializes in long-acting injectable treatments for opioid use disorder.
Indivior completes redomiciliation from UK to US By Investing.com
Indivior Pharmaceuticals, Inc. has officially completed its redomiciliation from the United Kingdom to the United States, transitioning its parent company to a new Delaware corporation and renaming the former PLC to a wholly-owned subsidiary. This strategic move aims to strengthen its U.S. capital markets presence, improve potential U.S. equity indexation, simplify corporate governance, and align the company closer to U.S. public health leaders. The company, which specializes in treatments for opioid use disorder, saw its stock surge 174.98% over the past year and recently provided strong financial guidance for 2026, surpassing analyst expectations.
Indivior completes redomiciliation from UK to US
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, making a new Delaware corporation the parent company. This move aims to strengthen its U.S. capital markets presence and simplify corporate governance. The company's stock has surged, and it projects strong financial performance for 2026, driven by its SUBLOCADE treatment for opioid use disorder.
Indivior announces completion of redomiciliation to U.S.
Indivior has completed its redomiciliation from the United Kingdom to the United States. The company's new parent entity is Indivior Pharmaceuticals, a Delaware corporation, whose common stock is now listed on Nasdaq under the symbol "INDV." Indivior PLC has been renamed Indivior and is now a wholly-owned subsidiary.
Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the United Kingdom to the United States, appointing a new Delaware corporation, IPI, as its parent company. This move aims to strengthen its U.S. capital markets presence, simplify corporate governance, and enhance its position as a U.S.-based treatment innovator. Indivior's common stock will continue to trade on Nasdaq under the symbol “INDV.”
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq
Indivior Pharmaceuticals (INDV) has successfully moved its corporate headquarters from the UK to the US, establishing a new Delaware-based parent company and retaining its Nasdaq listing. The company specializes in manufacturing prescription drugs for substance use disorders and mental illnesses, with significant revenue generated in the U.S. Indivior exhibits robust financial performance with strong revenue growth and high gross margins, though its liquidity ratios and P/E and P/S ratios suggest a mixed financial outlook and potential overvaluation.
Indivior completes redomiciliation from UK to US By Investing.com
Indivior Pharmaceuticals, Inc. has officially completed its redomiciliation from the United Kingdom to the United States, with the new Delaware corporation now serving as the parent company. This strategic move aims to enhance its U.S. capital markets presence, simplify governance, and strengthen ties with U.S. public health leaders. The company also announced strong financial guidance for 2026, projecting increased net revenue and adjusted EBITDA, driven significantly by its SUBLOCADE treatment for opioid use disorder.
Indivior completes redomiciliation from UK to US
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, making a new Delaware corporation the parent company. This move aims to strengthen its U.S. capital markets presence, simplify governance, and align closer with U.S. public health leaders, as the company specializes in treatments for opioid use disorder. Indivior's stock has surged 174.98% over the past year, and recent financial guidance for 2026 surpassed analyst expectations, driven by strong growth projections for its SUBLOCADE treatment.
Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the United Kingdom to the United States, making a new Delaware corporation, IPI, the parent company. Indivior PLC is now Indivior Ltd. and a wholly-owned subsidiary of IPI. This move is expected to strengthen Indivior's U.S. capital markets presence, simplify corporate governance, and further position it as a U.S.-based treatment innovator.
Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. announced the completion of its redomiciliation from the United Kingdom to the United States, making a new Delaware corporation, IPI, the parent company. The company believes this change will strengthen its U.S. capital markets presence, simplify corporate governance, and enhance its position as a U.S.-based treatment innovator. IPI's common stock will continue to trade on Nasdaq under the symbol "INDV," and shareholders of the former Indivior PLC received one new IPI common share for each ordinary share held.
Indivior PLC: Can a Focused Addiction-Treatment Portfolio Power the Next Wave of Growth?
Indivior PLC is focusing on addiction medicine, particularly opioid use disorder, with a strategy centered on buprenorphine-based therapies, long-acting injectables, and a diversifying pipeline. The company aims to differentiate itself from generics and competitors like Alkermes and Camurus by emphasizing clinical specialization, adherence-driven outcomes, and alignment with public health priorities. Indivior's future valuation and stock performance depend on its ability to transition its portfolio towards higher-margin, differentiated treatments and prove their effectiveness in improving patient outcomes.
